Services
Company
Legal and Governance
Insights / Whitepapers
The Golden Era: Unlocking Opportunities for Small and Midsize Biopharma
Written on Thursday, September 26, 2024
Overcoming challenges on the path to innovation
In the rapidly evolving world of biopharma, the influence of small and midsize companies is expanding. Despite big pharma spending over $10 billion annually on R&D, their clinical pipeline share is shrinking. The forecast for small and midsize biopharma companies shows a remarkable compound annual growth rate (CAGR) of 11% from 2020 to 2025—more than double that of their larger counterparts.
This whitepaper delves into how small and midsize biopharma companies are driving groundbreaking innovation, conducting nearly half of U.S. clinical trials and maintaining higher success rates than larger firms. It explores the unique challenges these companies face—limited infrastructure, tight budgets, and lean teams—while demonstrating how the right partnerships can turn these hurdles into opportunities.
Featuring insights from industry leaders at OPEN Health and Acsel Health (an OPEN Health company), this paper:
- Examines how to overcome challenges and capitalize on this golden era of biopharma innovation
- Reviews strategies for navigating complex clinical landscapes, optimizing market access, and communicating the value of innovations to investors, healthcare providers, and the broader community
- Explores how partnering with the right experts can unlock opportunities, streamline operations, and ensure scientific narratives resonate with key stakeholders
Contributors:
